Headlines about ProQR Therapeutics (NASDAQ:PRQR) have been trending positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ProQR Therapeutics earned a daily sentiment score of 0.35 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 44.5770459063824 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

A number of research analysts have commented on the stock. Zacks Investment Research raised shares of ProQR Therapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a research report on Wednesday, January 10th. Chardan Capital reissued a “neutral” rating on shares of ProQR Therapeutics in a research report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $18.88.

Shares of ProQR Therapeutics (PRQR) traded up $0.12 on Tuesday, hitting $3.02. 57,300 shares of the stock traded hands, compared to its average volume of 127,383. The firm has a market capitalization of $92.39, a PE ratio of -1.59 and a beta of 0.60. ProQR Therapeutics has a 1-year low of $2.75 and a 1-year high of $6.90. The company has a debt-to-equity ratio of 0.20, a current ratio of 6.72 and a quick ratio of 6.72.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Monday, November 20th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. equities research analysts forecast that ProQR Therapeutics will post -2.06 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “ProQR Therapeutics (PRQR) Earning Favorable News Coverage, Report Finds” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/02/13/proqr-therapeutics-prqr-earning-favorable-news-coverage-report-finds.html.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.

Insider Buying and Selling by Quarter for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.